Margarida Maia, PhD, science writer —

A Phase 1b/2 clinical trial testing WRAIR-PAM-CF1, Adaptive Phage’s experimental cocktail of bacteriophages, or viruses that selectively target and kill bacteria, is now recruiting cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infections. The study (NCT05453578) seeks to enroll up to 72 adults with CF who test positive…

Trikafta (elexacaftor/tezacaftor/ivacaftor) may bring health-related quality of life benefits to people with cystic fibrosis (CF) that go beyond those already reported for breathing, a study found. This expectation stems from a new look by an international team of researchers into data from the two Phase 3 clinical trials that…

The bacteria that causes chronic rhinosinusitis — swelling of the nasal cavity and sinuses — in people with cystic fibrosis (CF) are also those that often seed infections in their lungs, which means preventing or treating sinus disease may help better manage the symptoms of CF, a study suggests.

Young patients with cystic fibrosis (CF) who have a lung infection caused by Staphylococcus bacteria may have worse lung function and more exacerbations than those who are infected with Pseudomonas bacteria, a Brazilian study has found. The study, “Lower airway microbiota and decreasing lung function in young Brazilian…

A type of ring-shaped molecule called a macrocycle can help CFTR — the faulty protein in cystic fibrosis (CF) — go to the cell’s membrane, where it exerts its action, and work better in lab-grown cells carrying the most common CF-causing mutation, a study showed. These benefits were associated…

Kaftrio, a triple combination of elexacaftor, tezacaftor, and ivacaftor sold as Trikafta in the U.S., may ease acid reflux and symptoms of nasal and sinus cavity infection in cystic fibrosis (CF) patients with advanced lung disease, a U.K.-based study found. The study, “Elexacaftor-tezacaftor-ivacaftor improve gastro-oesophageal reflux and…

Taking so-called CFTR modulators — medications to correct the disease-causing faulty CFTR protein in cystic fibrosis (CF) — may significantly reduce a patient’s risk of severe COVID-19, according to a study by an international team of researchers. In fact, non-lung transplant CF patients in the U.S. and the U.K. using…

Wheezing — noisy breathing with a whistling sound — occurs in nearly three of every four preschool-aged children with cystic fibrosis (CF), and its presence at age 6 is linked to worse lung function, a French study has found. Researchers also observed that the majority of older children and…

Lab-edited transfer RNA (tRNA) molecules revived the production of a protein that’s lost or faulty in cystic fibrosis patients’ cells that carry mutations in the protein’s coding gene, a study found. They did this by helping the cell machinery read through the mutations that would cause protein production to…

CF-370, an expeimental therapy by ContraFect, reduces the number of hard-to-treat Pseudomonas aeruginosa bacteria in a rabbit model of pneumonia, an infection that inflames the lungs. P. aeruginosa, the most common cause of lung infections in people with cystic fibrosis (CF), can evade the body’s immune…